It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Systolic and diastolic dysfunction in diabetes have frequently been associated with abnormal calcium (Ca2+) regulation. However, there is emerging evidence that Ca2+ mishandling alone is insufficient to fully explain diabetic heart dysfunction, with focus shifting to the properties of the myofilament proteins. Our aim was to examine the effects of diabetes on myofilament Ca2+ sensitivity and Ca2+ handling in left ventricular tissues isolated from the same type 2 diabetic rat hearts. We measured the force-pCa relationship in skinned left ventricular cardiomyocytes isolated from 20-week-old type 2 diabetic and non-diabetic rats. Myofilament Ca2+ sensitivity was greater in the diabetic relative to non-diabetic cardiomyocytes, and this corresponded with lower phosphorylation of cardiac troponin I (cTnI) at ser23/24 in the diabetic left ventricular tissues. Protein expression of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), phosphorylation of phospholamban (PLB) at Ser16, and SERCA/PLB ratio were lower in the diabetic left ventricular tissues. However, the maximum SERCA Ca2+ uptake rate was not different between the diabetic and non-diabetic myocardium. Our data suggest that impaired contractility in the diabetic heart is not caused by SERCA Ca2+ mishandling. This study highlights the important role of the cardiac myofilament and provides new insight on the pathophysiology of diabetic heart dysfunction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Otago, Department of Medicine and HeartOtago, Otago Medical School, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830); University of Otago, Department of Physiology and HeartOtago, School of Biomedical Sciences, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)
2 University of Otago, Department of Physiology and HeartOtago, School of Biomedical Sciences, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)
3 University of Otago, Department of Pharmacology and Toxicology and HeartOtago, School of Biomedical Sciences, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)
4 University of Wisconsin-Madison, Department of Kinesiology, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675)
5 University of Otago, Department of Medicine and HeartOtago, Otago Medical School, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)